Site-directed mutagenesis was performed using 50 ng of KAT3A/CBP (
CREBBP) (NM_004380)
Human Tagged ORF Clone (OriGene) as the dsDNA template. This was carried out using the
QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) according to the manufacturer’s protocol with the following exception:
One Shot™ Stbl3™ Chemically Competent E. coli (Invitrogen) was used for transformation rather than the XL10-Gold Ultracompetent Cells supplied with the kit because of the dependency on chloramphenicol selection already found in the full-length
CREBBP vector. Mutagenic oligonucleotide primers were designed using Agilent QuickChange Primer Design program and purchased from Sigma-Aldrich with PAGE purification with the following sequences:
5′-tggatgcagcgctagatgctcagccgg-3′
5′-ccggctgagcatctagcgctgcatcca-3′
Following transformation, single colonies were selected on LB plates containing 34ug/mL chloramphenicol, expanded in LB broth containing 34ug/mL chloramphenicol overnight, and extracted with a
QIAfilter midi kit (Qiagen). Sanger sequencing was utilized to confirm the presence of the desired mutation. Mutant plasmids were directly transfected into cell lines using
GeneJet transfection reagent (SignaGen Labs) or packaged in 293T for lentiviral infection.
Kumar M., Molkentine D., Molkentine J., Bridges K., Xie T., Yang L., Hefner A., Gao M., Bahri R., Dhawan A., Frederick M.J., Seth S., Abdelhakiem M., Beadle B.M., Johnson F., Wang J., Shen L., Heffernan T., Sheth A., Ferris R.L., Myers J.N., Pickering C.R, & Skinner H.D. (2021). Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nature Communications, 12, 6340.